Creator: Help Dementia Editorial Team
Published: 2026-04-09T02:49:26

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Access barriers sits at the center of this dementia and brain health question.

New Alzheimer’s treatments approved in recent years—including lecanemab (Leqembi, FDA approved July 2023) and donanemab (FDA approved July 2024)—show promise in slowing cognitive decline in early-stage disease, yet access to these medications remains severely limited across the globe. While patients in some wealthy nations may gain access, the same treatments are either unavailable, unaffordable, or restricted in other developed countries and remain inaccessible to the vast majority of people living with Alzheimer’s disease worldwide. The barriers preventing global access are multifaceted: prohibitive costs that exceed healthcare budgets, diagnostic infrastructure that exists only in wealthy regions, complex treatment regimens requiring frequent clinical visits, and regulatory decisions that vary dramatically by country. The disparity is striking when examined closely.

In Europe, if these medications were priced at American levels, the annual treatment cost would exceed €133 billion per year—representing more than half of all pharmaceutical expenditures across the entire European Union. This economic reality has prompted the European Medicines Agency to withdraw approval of lecanemab for broader patient populations. Meanwhile, in Australia, the biomarker diagnostic tests required to identify eligible patients are only available in metropolitan centers and are not covered by Medicare, placing treatment entirely out of reach for rural populations. The new treatments that generated headlines and hope are becoming medicines accessible primarily to wealthy patients in wealthy countries.

Why Are New Alzheimer’s Treatments Geographically Limited?
The Cost Barrier That Makes Treatment Economically Impossible in Many Nations
Diagnostic Requirements Create Infrastructure Barriers That Exclude Most Patients
The Infusion Burden: Treatment Infrastructure That Exists Only in Wealthy Settings
Equity Gaps and Historical Barriers Within High-Income Nations
Regulatory Inconsistency Creates Confusion and Delays Patient Access
Resource-Limited Settings and the Path Forward
Conclusion

Why Are New Alzheimer’s Treatments Geographically Limited?

The global availability of new Alzheimer’s treatments depends on overlapping regulatory, economic, and infrastructural decisions that differ significantly from country to country. Lecanemab received FDA accelerated approval in January 2023 and full approval seven months later, but this American regulatory pathway bears little relationship to what happened in Europe. The European Medicines Agency actually reversed its decision to approve lecanemab in November 2024, restricting it only to patients with zero or one copy of the APOE ε4 allele—a genetic variant directly related to Alzheimer’s risk. This narrower approval came after cost analyses demonstrated the unsustainable burden on European healthcare systems.

The timeline and scope of approvals reveal how regulatory decisions are shaped by economic concerns alongside clinical evidence. Donanemab, the second anti-amyloid monoclonal antibody to reach patients, was approved by the FDA in July 2024 but has only received approval in Japan among other nations thus far. Lecanemab has been approved in China, Israel, South Korea, and the United Arab Emirates—all without the genetic restrictions Europe imposed—yet these approvals do not necessarily translate to real patient access. A patient in Seoul with early Alzheimer’s disease might have regulatory approval but still face prohibitive out-of-pocket costs or waiting lists that can extend treatment access for months. The fragmentation of global approval processes means the same disease, the same drug, and the same patient outcomes are evaluated and deemed worthwhile in one country but not another.

Why Are New Alzheimer's Treatments Geographically Limited?

The Cost Barrier That Makes Treatment Economically Impossible in Many Nations

The price structure of new Alzheimer’s medications creates an immediate barrier that no amount of regulatory approval can overcome. If lecanemab and donanemab were made available at their current American prices across Europe, the annual cost to treat the entire continent would exceed €133 billion annually. To place this in perspective, that figure represents more than half of the entire European Union’s total pharmaceutical spending. No healthcare system in Europe is structured to absorb that cost, and this mathematical reality is why cost considerations, not clinical efficacy, ultimately drove the European Medicines Agency’s narrow approval decision.

The pricing structure reflects the American market where treatment costs can reach $26,500 annually per patient. In the United States, these costs are often partially offset by insurance or Medicare, but this model exists nowhere else in the world. Even in other high-income nations with robust healthcare systems, the price point is unsustainable when multiplied across entire aging populations. A patient diagnosed with mild cognitive impairment at age 65 could potentially require a decade of treatment costing over $265,000—a burden that transforms access to the treatment into an economic privilege rather than a medical decision. The limitation here is not ambition or willingness to help patients; it is economic arithmetic that simply does not work at global scale.

Diagnostic Requirements Create Infrastructure Barriers That Exclude Most Patients

Before a patient can receive lecanemab or donanemab, they must undergo biomarker testing to confirm amyloid pathology in the brain. This requirement sounds straightforward until you examine where these diagnostic tools actually exist. Amyloid PET imaging and cerebrospinal fluid (CSF) testing are the primary methods used to detect amyloid, yet both require specialized equipment and expertise found almost exclusively in academic medical centers and wealthy urban areas. In Australia, biomarker diagnostic methods are only available in metropolitan centers and are not covered by Medicare, meaning that patients in rural or regional areas face an insurmountable first barrier before treatment consideration.

The diagnostic infrastructure disparity extends beyond geography into equity concerns. research from the USC Schaeffer Center documents that neuroimaging centers—including the PET scanners and MRI machines needed for diagnosis—are predominantly located in affluent, predominantly White neighborhoods. This geographic clustering means that minority communities face both logistical barriers (distance, transportation) and systemic barriers (historical distrust of medical institutions, prior experiences with healthcare discrimination). In low- and middle-income countries, the situation is even more severe: amyloid biomarker testing is largely unavailable, meaning patients cannot be diagnosed with the specific form of cognitive decline that these medications treat. The diagnostic barrier is not a minor inconvenience; it is often the decisive factor determining whether treatment is even possible.

Diagnostic Requirements Create Infrastructure Barriers That Exclude Most Patients

The Infusion Burden: Treatment Infrastructure That Exists Only in Wealthy Settings

The medications themselves—lecanemab and donanemab—are monoclonal antibodies that must be delivered intravenously. This means patients require infusions every 2-4 weeks, each requiring a visit to a medical facility equipped to administer IV medications and monitor for adverse effects. These appointments are not quick office visits; infusion appointments typically require 1-2 hours of clinical time. Additionally, patients must undergo regular MRI monitoring to watch for amyloid-related imaging abnormalities (ARIA)—a potential side effect where amyloid plaques are cleared so rapidly that microhemorrhages or microinfarcts can occur. This monitoring requirement adds substantial cost and logistical burden.

For patients in major urban centers with established neurology departments, the infusion schedule may be manageable, though inconvenient. For patients in rural areas, smaller towns, or developing nations, the requirement for biweekly infusions at a specialized center is often disqualifying. The burden falls heaviest on patients with limited mobility, those without reliable transportation, or those balancing treatment with work and family responsibilities. However, regulatory advances have begun to address this limitation. The FDA approved an at-home injectable form of lecanemab that allows patients to self-administer the medication rather than requiring clinic visits. This development represents genuine progress in reducing access barriers, though the at-home formulation is not yet available everywhere and does not address the cost or diagnostic barriers that precede it.

Equity Gaps and Historical Barriers Within High-Income Nations

Even within wealthy nations with advanced healthcare infrastructure, access to new Alzheimer’s treatments is stratified by race, ethnicity, and socioeconomic status. Black Americans face distinctive barriers to accessing these medications, including historical distrust of the healthcare system rooted in documented past abuses, current access barriers created by geography and insurance coverage, and legitimate concerns about treatment side effects and costs. These barriers are not hypothetical: they reflect real disparities in which patients receive diagnosis of early-stage Alzheimer’s disease versus later presentations that may not be eligible for the new medications. The equity limitation is particularly consequential because Alzheimer’s disease itself affects some racial and ethnic groups disproportionately.

Some research suggests Black Americans experience higher rates of cognitive impairment than White Americans at similar ages, yet are less likely to receive a formal diagnosis of mild cognitive impairment or early-stage dementia. If new treatments are available only to those who have received a diagnosis, and diagnostic rates vary by race and socioeconomic status, the medications will amplify existing health disparities. This creates a compounding injustice: populations with greater disease burden receive diagnostic services less frequently and therefore gain access to new treatments at lower rates. Addressing this barrier requires not only making medications available but transforming how early-stage cognitive decline is identified and diagnosed across all communities.

Equity Gaps and Historical Barriers Within High-Income Nations

Regulatory Inconsistency Creates Confusion and Delays Patient Access

The regulatory landscape for new Alzheimer’s treatments is fragmented across jurisdictions in ways that delay and limit patient access. As noted, the European Medicines Agency approved lecanemab with significant restrictions after rejecting a broader approval, while the FDA maintained broader approval criteria in the United States. Japan approved donanemab but not lecanemab. China approved lecanemab without genetic restrictions.

Each regulatory body makes independent decisions based on its own health technology assessment process, cost-benefit analysis, and healthcare priorities. This regulatory patchwork means that a medication deemed clinically effective and worth the cost in one country is simultaneously deemed too expensive or too narrow in application in another. The uncertainty also affects pharmaceutical companies’ decisions about where to seek approval and at what price point, sometimes discouraging market entry in smaller or lower-income countries where approval might be obtained but profits would be limited. For patients, the inconsistency creates a situation where access depends fundamentally on geography rather than medical need.

Resource-Limited Settings and the Path Forward

In regions with limited healthcare resources—including low- and middle-income countries and rural areas of wealthier nations—the new medications remain aspirational rather than practical. These settings cannot realistically expect to offer lecanemab or donanemab to the majority of patients with Alzheimer’s disease. However, this reality does not mean abandonment or therapeutic nihilism.

Conventional treatments including acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine remain clinically important and should be optimized across all settings. For these regions, the path forward involves expanding access to basic diagnostic capacity, improving training for healthcare workers in dementia recognition and management, and ensuring that existing medications are used effectively. The future may hold more accessible options: oral or at-home formulations of newer treatments, lower-cost alternatives as patents expire, and simplified diagnostic approaches that do not require expensive imaging. Until these advances materialize, strategies for expanding access must focus on conventional treatments, prevention through management of modifiable risk factors (cardiovascular health, cognitive activity, social engagement), and building diagnostic infrastructure that does not depend entirely on expensive imaging technology.

Conclusion

The new Alzheimer’s treatments approved in 2023 and 2024 represent genuine scientific progress in slowing cognitive decline, yet their real-world impact on patients globally is sharply limited by interconnected barriers: cost structures that exceed healthcare budgets, diagnostic infrastructure concentrated in wealthy regions, treatment requirements that assume access to specialized medical facilities, regulatory decisions that vary by jurisdiction, and equity gaps that perpetuate disparities in who receives early diagnosis. These barriers mean that access to the new medications functions as a proxy for wealth and geography rather than as a response to medical need.

Understanding these barriers is the first step toward addressing them. Policymakers, healthcare systems, and pharmaceutical companies face choices about pricing, diagnostic accessibility, and treatment delivery methods. Patients and families should be realistic about current access while advocating for the investments in diagnostic infrastructure, healthcare worker training, and treatment innovation that could eventually make truly effective Alzheimer’s treatments available to all who need them, not merely to those who can afford them.